Senti Biosciences, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Senti Biosciences reports on Q1 2026, detailing a significant lease amendment with GeneFab, a reduction in operating expenses, and a subsequent financing agreement.
NASDAQ
Senti Biosciences reports significant net losses and dwindling cash, raising substantial doubt about its going concern ability, while its partner halts a clinical trial due to toxicities.
NASDAQ
Senti Biosciences reports increased net losses and significant cash burn, raising substantial doubt about its ability to continue as a going concern, despite progress with SENTI-202 and recent capital raises.
NASDAQ
Senti Biosciences reports a net loss of $14.1 million for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern.
NASDAQ
Senti Biosciences reports a net loss of $28.9 million for the third quarter of 2024, alongside updates on clinical development and strategic partnerships.
NASDAQ
10-Q: Senti Biosciences Reports Second Quarter 2024 Financial Results, Cites Going Concern Uncertainty
Senti Biosciences' second quarter 2024 results show a net loss of $11.2 million, with management expressing substantial doubt about the company's ability to continue as a going concern.
NASDAQ
Senti Biosciences reported a net loss of $12.1 million for the first quarter of 2024 and expressed substantial doubt about its ability to continue as a going concern.